Administration of Vorolanib — Competitive Intelligence Brief

Administration of Vorolanib (Administration of Vorolanib) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGFR tyrosine kinase inhibitor. Area: Oncology.

phase 2 VEGFR tyrosine kinase inhibitor VEGFR (vascular endothelial growth factor receptor) Oncology Small molecule

Target snapshot

Administration of Vorolanib (Administration of Vorolanib) — Li-kun Chen. Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) to inhibit angiogenesis and tumor growth.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Administration of Vorolanib TARGET	Administration of Vorolanib	Li-kun Chen	phase 2	VEGFR tyrosine kinase inhibitor	VEGFR (vascular endothelial growth factor receptor)
Combination PD-1/PD-L1 ICI + VEGFR-TKI	Combination PD-1/PD-L1 ICI + VEGFR-TKI	University Hospital, Bordeaux	phase 3	PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination	PD-1, PD-L1, VEGFR (vascular endothelial growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGFR tyrosine kinase inhibitor class)

1. Li-kun Chen · 1 drug in this class